Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Incyte (INCY) PT Raised to $140 at Jefferies on 4Q Report, Jakafi Metrics
February 15, 2017 8:10 AM ESTJefferies analyst Brian Abrahams reiterates Buy rating and raises price target on Incyte Corp. (NASDAQ: INCY) to $140 (from $136) as the company delivered in-line Jakafi sales figures, while offering positive guidance.
Abrahams comments, "Solid, unsurprising Valentine's Day 4Q report, with good Jakafi metrics and... More
RBC Capital Reiterates Outperform Rating on Incyte (INCY) Following 4Q Results
February 14, 2017 9:37 AM ESTRBC Capital Markets analyst Simos Simeonidis reiterates Outperform rating on Incyte Corporation (NASDAQ: INCY) suggesting Jakafi continues to grow, despite the company reporting 2016 fourth quarter revenues below consensus.
Simeonidis comments, INCY reported slightly below consensus Jakafi/total revenue numbers, despite decent growth five years... More
Incyte (INCY) Misses Q4 EPS by 8c
February 14, 2017 7:11 AM ESTIncyte (NASDAQ: INCY) reported Q4 EPS of $0.05, $0.08 worse than the analyst estimate of $0.13. Revenue for the quarter came in at $326 million versus the consensus estimate of $324.42 million.
For earnings history and earnings-related data on Incyte (INCY) click here.
... More